COMP <GO>
BIIB vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Biogen Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BIIB 4
— JNJ 9
■ METRIC PARITY
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
options-implied-move
7.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 67.90% | +7.80 | BIIB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 25.50% | -19.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | 18.5x | +3.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 2.97% | +2.59 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | 34.70% | -18.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 28.50% | -15.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 6.00% | -3.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 5.59 | -1.89 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 60.4 | +6.30 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 23.0x | +3.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $662.49B | -$625.59B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | JNJ REV | BIIB GROSS % | JNJ GROSS % | BIIB FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $94.19B | 75.7% | 67.9% | $2.05B | $19.70B |
| FY 2024 | $9.68B | $88.82B | 76.1% | 69.1% | $2.72B | $19.84B |
| FY 2023 | $9.84B | $85.16B | 44.0% | 44.0% | $1.10B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
JNJ // BETA 1.08